HomeReimbursement
Content Holder

Terms of Use

PLEASE READ CAREFULLY THE FOLLOWING TERMS OF USE, WHICH APPLY TO EVERYBODY WHO VISITS THE SITE. IF YOU PROCEED TO USE THIS SITE, YOU ARE AGREEING TO ABIDE BY THESE RULES.

CSL Behring reserves its right to make additions, deletions, or modifications to the information at any time without prior notification. Provisions of the Terms of Use do not create any contractual or other legal right in or on behalf of any party.

Site information

As a leading innovation-driven Pharmaceutical company, CSL Behring is committed to playing a major role in improving the quality of life. This site gives you insights into CSL Behring, its worldwide subsidiaries, and related industry information. To facilitate the use of this site, we provide you with tailored information dependent upon the purpose of your respective visit, be it as a patient, healthcare professional, investor or prospective employee.

PLEASE NOTE THAT NO INFORMATION IN THIS SITE IS PROVIDED WITH THE INTENTION OF OR SHOULD BE VIEWED AS GIVING MEDICAL ADVICE OR INSTRUCTION ON THE CORRECT USE OF CSL BEHRING'S PRODUCTS.

CSL Behring offers the information on this Web site for general educational and informational purposes only. This information is not intended as a substitute for advice, treatment, or recommendations from health care professionals. It is important to follow the advice of your physician and other health care professionals regarding your individual medical and health care needs. Please consult with your physician or other health care professional before using any drug product discussed within this Web site. CSL Behring is not engaged in rendering medical advice or services.

No Guarantee or Warranty

CSL Behring is committed to keeping its site up-to-date. However, CSL Behring does not guarantee the accuracy and completeness of any information contained in this site. Except for direct damages caused by CSL Behring's willful misconduct or gross negligence, CSL Behring is not liable for any direct, indirect, special, punitive, incidental, or other consequential damages arising out of or in connection with your visit to this Web site, including, without limitation, lost profits, business interruption, and loss of programs or electronic data.

For the convenience of our visitors, CSL Behring provides links to other Web sites. However, certain links on this site lead to resources located on servers maintained by third parties over whom CSL Behring has no control. CSL Behring is not responsible for third party content or the consequences of your use thereof.

Expert Advice or Opinion

As a useful resource to our visitors this site may contain expert opinions. Information in this site identified as expert opinion, or accessed from this site by hyperlink, represents the opinions of these respective experts, which are not necessarily those of CSL Behring. Such experts are not employees of CSL Behring and do not receive any compensation from CSL Behring for the use of their opinions. CSL Behring does not endorse, and is not responsible for, the accuracy or completeness of any information or opinions set forth in such materials. Please note that expert advice reflects only the personal view of that expert -- in no case shall it be regarded as the opinion or responsibility of CSL Behring.

Country-specific product information

CSL Behring provides information with respect to its global and local pharmaceutical business that might not be relevant to every visitor around the world. For example, trademarks used for certain products may differ from country to country. Furthermore, in some countries regulatory authorities may approve products for sale with different indications, dosages and restrictions. If CSL Behring's products, programs and services mentioned in this site are not available in your country, any such reference does not imply that CSL Behring intends to announce these products, programs or services in your country. Consult your local CSL Behring contact or your physician for further information as to the availability of our products in your country. Due to laws specific to different jurisdictions, we may not be able to provide all visitors with information on our prescription drugs. CSL Behring intends to disclose country-specific product information primarily to healthcare professionals and, only where permissible, to the general public.

Communities

In any forum for discussion on this site, CSL Behring expects the participants to observe common rules for communication, such as mutual respect for others. Visitors must not distribute or publish any offensive, abusive, indecent, defamatory or obscene material or any material that breaches a third party’s intellectual property rights.

Information deemed non-confidential

Unless stated otherwise in our Web Privacy Policy, any communication from you to CSL Behring via this site shall be deemed to be non-confidential and non-proprietary. CSL Behring shall be free to use any information, including but not limited to ideas, concepts, know-how or techniques, contained in such communication for any purpose, without compensation to you and without identifying the source.

Intellectual Property

Please note that it is CSL Behring's policy to enforce its intellectual property rights to the utmost extent as set forth in applicable laws, including criminal sanctions. The trademarks, logos and service marks (collectively the "Trademarks") displayed on this site are Trademarks owned or licensed by CSL Behring. Nothing on this site should be construed as granting, by implication or otherwise, any license or right in or to the Trademarks without the express written permission of CSL Behring or, if not CSL Behring, the owner of the Trademark. In addition, any reproduction, retransmission, modification or use of this site's content for other than personal, non-commercial purposes requires the prior written consent of CSL Behring. The following copyright notice must appear on every copy of the contents of this site or a portion thereof: Copyright © 2007 CSL Behring.

IMPORTANT SAFETY INFORMATION

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isoimmunization, Rhophylac® can be administered IM or IV.

Rhophylac® is indicated to raise platelet counts in Rho(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP). For the treatment of ITP, Rhophylac® must be administered IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Suppression of Rh Isoimmunization: For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Immune Thrombocytopenic Purpura: The most serious adverse reactions in patients receiving Rho(D) immune globulin have been observed in the treatment of ITP. ITP patients being treated with Rhophylac® should be monitored for signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and hemoglobinuria. Potentially serious complications of intravascular hemolysis include clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation, and death.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis has also been observed. In patients with preexisting anemia, weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.